MindImmune Therapeutics

Executive Summary

MindImmune Therapeutics is a private biotechnology company pioneering a novel immunotherapeutic approach to neurodegenerative diseases. Founded in 2018 and based in San Diego, the company leverages the immune system to combat neuroinflammation, a key driver of conditions such as Alzheimer's and Parkinson's disease. Its lead candidate, MITI-101, is a first-in-class monoclonal antibody designed to prevent harmful peripheral immune cells from crossing the blood-brain barrier, thereby preserving neural connections and protecting brain health. By targeting the immune component of neurodegeneration, MindImmune aims to address a significant unmet medical need in a field dominated by symptomatic treatments. The company is currently in the preclinical stage, focusing on advancing MITI-101 toward clinical development. MindImmune's strategy capitalizes on the growing understanding of the immune system's role in brain health. Its differentiated approach could offer a disease-modifying therapy if successfully translated. However, as a private early-stage company with no disclosed funding rounds or valuation, the path to commercialization is uncertain and heavily dependent on future capital raises and clinical trial outcomes. The company's potential is substantial, but near-term visibility is limited. Key upcoming catalysts include regulatory milestones and clinical trial initiations that will test the therapeutic hypothesis.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance of IND Application for MITI-10170% success
• Q4 2026Initiation of Phase 1 Clinical Trial for MITI-10165% success
• H2 2026Presentation of Preclinical Efficacy Data at Major Neuroscience Conference80% success